Drugs / Oryzanol
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04481841 | Jul 2020 → Feb 2022 | burning mouth syndrome, mouth mucosa disorder | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| — | NCT05922800 Comparator | Jun → Dec 2023 | — | Dongzhimen Hospital, Beijing | Unknown | No outcome recorded |
| — | NCT03674853 Comparator | Jun 2018 → Oct 2019 | tinnitus | Xijing Hospital | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | oryzanol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04481841 ↗ |
| Known as | gamma-oryzanol | “The patients in this group were given orally gamma-oryzanol tablets 20mg each time, three times a day, for 6 months.” NCT05922800 ↗ |
| Route | Oral | “oryzanol tablets, oral, 10 mg/time, 3 times/day” NCT04481841 ↗ |